The role of COX-2 and Ki-67 over-expression in the prediction of pathologic response of rectal cancer to neoadjuvant chemoradiation therapy

2016 ◽  
Vol 53 (4) ◽  
pp. 548 ◽  
Author(s):  
ATaghizadeh Kermani ◽  
AH Jafarian ◽  
J Esmaeili ◽  
NM Roshan ◽  
M Seilanian-Toosi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Pathologic Response ◽  
Ki 67 ◽  
Over Expression ◽  
Neoadjuvant Chemoradiation Therapy ◽  
Cox 2

scholarly journals The Role of Cox-2 and KI-67 Overexpression in the Prediction of Pathologic Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy

2012 ◽  
Vol 23 ◽  
pp. ix184
Author(s):  
A. Taghizadeh Kermani ◽  
A. Jafarian ◽  
J. Esmaeili ◽  
N. Mohammadian Roshan ◽  
M. Seilanian Toosi ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Pathologic Response ◽  
Ki 67 ◽  
Neoadjuvant Chemoradiation Therapy ◽  
Cox 2

Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer

2015 ◽  
Vol 67 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Jacopo Martellucci ◽  
Giovanni Alemanno ◽  
Francesca Castiglione ◽  
Carlo Bergamini ◽  
Andrea Valeri
Keyword(s):  
Rectal Cancer ◽  
Kras Mutation ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Pathologic Response ◽  
Neoadjuvant Chemoradiation Therapy

scholarly journals Role of thymidylate synthase as a predictor of neoadjuvant chemoradiation therapy in rectal cancer

2017 ◽  
Vol 98 (4) ◽  
pp. 576-580
Author(s):  
Aliyarov Yu.R. ◽  
◽  
Melikova L.A. ◽  
Kerimov A.Kh. ◽  
Bagirova E.E. ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Thymidylate Synthase ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Neoadjuvant Chemoradiation Therapy

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after neoadjuvant chemoradiation therapy.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 760-760
Author(s):  
Chang-gon Kim ◽  
Minkyu Jung ◽  
Inkyung Jung ◽  
Sang Joon Shin ◽  
Seung Hoon Beom ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
P Value ◽  
Neoadjuvant Chemoradiation Therapy

760 Background: Clinical benefit of adjuvant chemotherapy (AC) is still controversial in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiation therapy (CRT) followed by total mesorectal excision (TME). We aim to explore the role of adjuvant chemotherapy with fluoropyrimidine for ypT0-3N0 patients. Methods: Patients with ypT0-3N0 rectal cancer after neoadjuvant CRT and TME were included using retrospective cohort of Yonsei Cancer Center. Patients were categorized according to receipt of adjuvant chemotherapy (AC vs. no AC). Disease free survival (DFS) and overall survival (OS) between treatment groups were compared using all patients’ cohort (APC) and propensity score-matched patients’ cohort (PSMPC). Results: total of 339 patients were evaluated. Of all, 87 patients (25.7%) did not receive AC. There was no difference in DFS between two groups [hazard ratio (HR) = 1.079, p-value = 0.782 in APC; HR = 1.22, p-value in PSMPC]. Also there was no difference in OS between two groups (HR = 1.140, p-value 0.717 in APC; HR = 1.366, p-value 0.472 in PSMPC). Advanced T stage and positive resection margin were associated with inferior DFS and OS by multivariate analysis. In subgroup analysis by baseline characteristics, we could not find any group with benefit of adjuvant chemotherapy. Conclusions: AC did not improve DFS and OS of patients with ypT0-3N0 rectal cancer after neoadjuvant CRT followed by TME. The role of AC in LARC with ypT0-3N0 after preoperative CRT should be evaluated in prospective randomized trials with larger sample size.

Sign in / Sign up

Export Citation Format

Share Document